Skip to main content

Advertisement

Figure 1 | Critical Care

Figure 1

From: Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations

Figure 1

Schematic and simplified presentation of coagulation, fibrinolysis and anticoagulant pathways. The coagulation cascade is started through activation of tissue factor (TF)-factor VII (FVIIa) complex. Several coagulation factors accelerate the conversion of prothrombin to thrombin. Activated protein C (APC) can inactivate coagulation factors Va and VIIIa. Antithrombin (AT) serves to block the action of multiple coagulation factors (for example, Xa and IIa). Tissue factor pathway inhibitor (TFPI) inhibits stepwise the activation of coagulation factors. The fibrinolytic system is designed to degrade clots and fibrin degradation products (FDP) are formed. The main inhibitor of the plasminogen activators is plasminogen activator inhibitor type 1 (PAI-1). +: stimulating effect; -: inhibiting effect. Adapted and modified from Tuinman et al. [59].

Back to article page